The Column Group Crossover Fund (TCGX)
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Early Stage, Growth, Late Stage, Pre-IPO
Geographical Focus
United States, Europe, China
Industries Focus
- Healthcare
- Life Sciences
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Regenerative Medicine
- Oncology
- Neurology
- Cardiology
- Endocrinology
- Infectious Diseases
- Immunology
- Genomics
- Rare Diseases
Investment Size:
10,000,000 to 50,000,000 USD
Investor Details Founded: 2021
The Column Group Crossover Fund (TCGX) is a venture capital firm investing in early-stage biotechnology companies. TCGX is the first crossover fund under The Column Group (TCG) ecosystem, dedicated to investing in later-stage private and public drug discovery companies. Launched in 2021, TCGX focuses on innovative pre-IPO and public companies, aiming to support the translation of cutting-edge science into products that will make a meaningful difference for patients. TCGX operates independently within the TCG ecosystem, which includes TCG Platform funds, TCG Opportunity funds, TCG Labs-Soleil, and TCG Crossover. TCGX's goal is to support the translation of cutting-edge science into products that will make a meaningful difference for patients. TCGX is operationally independent of The Column Group (TCG).
Requirements
- Innovative drug discovery companies
- Focus on unmet medical needs
- Pre-IPO and public companies
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Neurona Therapeutics
- Synthekine
- RAPT Therapeutics
- ORIC Pharmaceuticals
- Remix Therapeutics
- Accent Therapeutics
Mentioned In
-
$49.95
-
$14.95
-
$19.95
-
$24.95
-
$99.00
Claim this Investor
Are you an official representative of The Column Group Crossover Fund (TCGX)?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim